2024
Randomized Controlled Trial of Integrated Adherence Support to Improve Treatment Outcomes in Patients With Drug-resistant Tuberculosis and HIV
Perumal R, Wolf A, Zelnick J, Friedland G, Amico R, Daftary A, Boodhram R, Padayatchi N, Naidoo K, O'Donnell M. Randomized Controlled Trial of Integrated Adherence Support to Improve Treatment Outcomes in Patients With Drug-resistant Tuberculosis and HIV. 2024, a6948-a6948. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6948.Peer-Reviewed Original Research
2022
Experiences with Telemedicine for HIV Care During the COVID-19 Pandemic: A Mixed-Methods Study
Harsono D, Deng Y, Chung S, Barakat LA, Friedland G, Meyer JP, Porter E, Villanueva M, Wolf MS, Yager JE, Edelman EJ. Experiences with Telemedicine for HIV Care During the COVID-19 Pandemic: A Mixed-Methods Study. AIDS And Behavior 2022, 26: 2099-2111. PMID: 35064390, PMCID: PMC8782707, DOI: 10.1007/s10461-021-03556-7.Peer-Reviewed Original ResearchConceptsHIV careRe-engage patientsMixed-methods studyCare team membersRoutine clinical experienceCOVID-19 pandemicBenefits of telemedicineHIV clinicTelemedicine visitsTelemedicine appointmentsReimbursement concernsClinical experienceClinical staffCareAppropriate billingPatientsPWHTelemedicinePatient remote monitoringReimbursement methodsPandemicHIVClinicVisits
2020
Does Routinely Provided Directly Observed Treatment Improve Adherence to Bedaquiline in Patients with Drug-Resistant TB HIV in South Africa (Praxis Study)?
Wolf A, Braunlin H, Amico K, Zelnick J, Boodhram R, Orrell C, Daftary A, Friedland G, Padayatchi N, O'Donnell M. Does Routinely Provided Directly Observed Treatment Improve Adherence to Bedaquiline in Patients with Drug-Resistant TB HIV in South Africa (Praxis Study)? 2020, a2690-a2690. DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2690.Peer-Reviewed Original ResearchBedaquiline Adherence Mediates Sputum TB Culture Conversion in MDR/XDR-TB Patients Co-Infected with HIV
Mudd J, Wolf A, Zelnick J, Boodhram R, Orrell C, Daftary A, Friedland G, Padayatchi N, O'Donnell M. Bedaquiline Adherence Mediates Sputum TB Culture Conversion in MDR/XDR-TB Patients Co-Infected with HIV. 2020, a2691-a2691. DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2691.Peer-Reviewed Original Research
2017
A patient with central nervous system tuberculomas and a history of disseminated multi-drug-resistant tuberculosis
Kaplan SR, Topal J, Sosa L, Malinis M, Huttner A, Malhotra A, Friedland G. A patient with central nervous system tuberculomas and a history of disseminated multi-drug-resistant tuberculosis. Journal Of Clinical Tuberculosis And Other Mycobacterial Diseases 2017, 10: 9-16. PMID: 31720380, PMCID: PMC6830180, DOI: 10.1016/j.jctube.2017.12.004.Peer-Reviewed Case Reports and Technical NotesDrug-resistant tuberculosisResistant tuberculosisMulti-drug resistant (MDR) TBCentral nervous system tuberculomasCentral nervous system tuberculosisNervous system tuberculosisGlobal public health concernCause of deathIncrease of patientsDrug-resistant strainsPublic health concernExtrapulmonary diseaseMiddle-income countriesNeurological symptomsTreatment challengesTuberculosisHealth concernYoung menPatientsTuberculomaSymptomsDisease
2016
Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa
Gilbert JA, Shenoi SV, Moll AP, Friedland GH, Paltiel AD, Galvani AP. Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa. PLOS ONE 2016, 11: e0165614. PMID: 27906986, PMCID: PMC5131994, DOI: 10.1371/journal.pone.0165614.Peer-Reviewed Original ResearchConceptsTB/HIVTB/HIV controlHIV screeningHIV controlRural South AfricaLife yearsMonths of IPTMost life yearsHigh-incidence settingsWidespread prevalenceCost-effectiveness resultsProbabilistic sensitivity analysesHIV transmissionHigh burdenTreatment coverageUnknown patientsHIVHealthcare accessDrug resistanceActive casesMonthsLifetime usePatientsYearsScreeningRe-inventing adherence: toward a patient-centered model of care for drug-resistant tuberculosis and HIV
O'Donnell MR, Daftary A, Frick M, Hirsch-Moverman Y, Amico KR, Senthilingam M, Wolf A, Metcalfe JZ, Isaakidis P, Davis JL, Zelnick JR, Brust JC, Naidu N, Garretson M, Bangsberg DR, Padayatchi N, Friedland G. Re-inventing adherence: toward a patient-centered model of care for drug-resistant tuberculosis and HIV. The International Journal Of Tuberculosis And Lung Disease 2016, 20: 430-434. PMID: 26970149, PMCID: PMC4863995, DOI: 10.5588/ijtld.15.0360.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusDrug-resistant TBMedication adherenceNational TB Control ProgrammeDrug-resistant tuberculosisTB control programsPatient-centered modelPatient-centered careNew antimycobacterial agentsUnderstanding of adherenceHealth care systemAdherence supportTB-HIVObserved therapyImmunodeficiency virusComprehensive careTreatment outcomesTreatment supportTuberculosis diagnosticsPatientsCare systemCareAntimycobacterial agentsTreatment deliveryAdherence
2015
A Study of the Knowledge and Beliefs Held by Patients Infected With HIV and Their HIV Healthcare Providers Regarding Single-Tablet Regimens (STR). (KNABSTR Study)
Frank C, Kyriakides T, Omar A, Friedland G, Andrews L, Melbourne K, Kozal M. A Study of the Knowledge and Beliefs Held by Patients Infected With HIV and Their HIV Healthcare Providers Regarding Single-Tablet Regimens (STR). (KNABSTR Study). Open Forum Infectious Diseases 2015, 2: 1082. DOI: 10.1093/ofid/ofv133.795.Peer-Reviewed Original Research
2014
1698Characteristics and Outcomes Among Patients with MDR-TB Treated in a Decentralized Community-based Treatment Program in Rural KZN, South Africa
Jacobson K, Eksteen F, Moll A, Friedland G, Mngadi A, Larkan L, Mhlongo P, Shenoi S. 1698Characteristics and Outcomes Among Patients with MDR-TB Treated in a Decentralized Community-based Treatment Program in Rural KZN, South Africa. Open Forum Infectious Diseases 2014, 1: s454-s454. DOI: 10.1093/ofid/ofu052.1244.Peer-Reviewed Original ResearchImproved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial
Padayatchi N, Abdool Karim SS, Naidoo K, Grobler A, Friedland G. Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial. The International Journal Of Tuberculosis And Lung Disease 2014, 18: 147-154. PMID: 24429305, PMCID: PMC4770013, DOI: 10.5588/ijtld.13.0627.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisMDR-TB patientsSequential treatment armAnti-tuberculosis treatmentAntiretroviral treatmentTreatment armsFirst-line anti-tuberculosis treatmentMultidrug-resistant tuberculosis patientsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionOut-patient clinicDrug susceptibility resultsSAPiT trialTuberculosis patientsClinical outcomesEarly initiationTherapeutic effectVirus infectionMortality ratePatientsTherapeutic outcomesSmall sample sizeTreatmentSusceptibility resultsTuberculosis
2013
Natural ventilation reduces high TB transmission risk in traditional homes in rural KwaZulu-Natal, South Africa
Lygizos M, Shenoi SV, Brooks RP, Bhushan A, Brust J, Zelterman D, Deng Y, Northrup V, Moll AP, Friedland GH. Natural ventilation reduces high TB transmission risk in traditional homes in rural KwaZulu-Natal, South Africa. BMC Infectious Diseases 2013, 13: 300. PMID: 23815441, PMCID: PMC3716713, DOI: 10.1186/1471-2334-13-300.Peer-Reviewed Original ResearchConceptsTB transmission riskInfectious TB patientsTransmission riskTB patientsRural South AfricaDrug-resistant TBTB control effortsHealth care facilitiesPaucity of dataHousehold settingsRural KwaZulu-NatalPrevalent TBResistant TBTB transmissionCare facilitiesMultivariate analysisHIV areasVentilationAChSignificant decreaseWells-Riley equationPatientsRiskLow ventilationHour periodAdverse Events in an Integrated Home-Based Treatment Program for MDR-TB and HIV in KwaZulu-Natal, South Africa
Brust JC, Shah NS, van der Merwe TL, Bamber S, Ning Y, Heo M, Moll AP, Loveday M, Lalloo UG, Friedland GH, Gandhi NR. Adverse Events in an Integrated Home-Based Treatment Program for MDR-TB and HIV in KwaZulu-Natal, South Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2013, 62: 436-440. PMID: 23254152, PMCID: PMC3641171, DOI: 10.1097/qai.0b013e31828175ed.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisAdverse eventsAntiretroviral therapyCommon severe adverse eventsMDR-TB/HIVTreatment programConcurrent antiretroviral therapyMDR-TB patientsMDR-TB therapySevere adverse eventsHome-based treatment programHome-based care settingsRural KwaZulu-NatalMost patientsTherapy modificationConcurrent treatmentCare settingsHIVPatientsTherapyKwaZulu-NatalIntegrated HomeTolerabilityHypothyroidismTuberculosis‘Cough officer’ nurses in a general medical clinic successfully detect drug-susceptible and -resistant tuberculosis
Shenoi SV, Brooks RP, Catterick K, Moll AP, Friedland GH. ‘Cough officer’ nurses in a general medical clinic successfully detect drug-susceptible and -resistant tuberculosis. Public Health Action 2013, 3: 46-50. PMID: 25392815, PMCID: PMC4226409, DOI: 10.5588/pha.12.0056.Peer-Reviewed Original ResearchGeneral medical clinicDrug-resistant tuberculosisMedical clinicsClinic attendeesTB suspectsHuman immunodeficiency virus (HIV) patientsHigh HIV prevalence settingsZiehl-NeelsenProportion of patientsHIV prevalence settingsCulture-positive casesResource-limited settingsWorld Health OrganizationTB screeningVirus patientsHigh HIVResistant tuberculosisPatient populationTB prevalencePrevalence settingsReferral laboratoryTuberculosisDrug resistancePatientsClinicPharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment
Bruce R, Moody DE, Chodkowski D, Andrews L, Fang WB, Morrison J, Parsons TL, Friedland GH. Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment. The American Journal Of Drug And Alcohol Abuse 2013, 39: 80-85. PMID: 23421567, DOI: 10.3109/00952990.2013.764885.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneHuman immuno-deficiency virusBuprenorphine/Buprenorphine/naloxone treatmentAddition of raltegravirOpioid-dependence therapiesHIV-seronegative subjectsEffect of raltegravirOpioid withdrawalNaloxone treatmentPharmacokinetic interactionsNaloxone concentrationsHistorical controlsPharmacodynamic parametersPharmacodynamic studiesBaseline valuesRaltegravirNaloxoneBuprenorphineSignificant differencesTherapySubjectsPrimary metabolitesSteady-state evaluationPatients
2012
Nosocomial Transmission of Extensively Drug-Resistant Tuberculosis in a Rural Hospital in South Africa
Gandhi NR, Weissman D, Moodley P, Ramathal M, Elson I, Kreiswirth BN, Mathema B, Shashkina E, Rothenberg R, Moll AP, Friedland G, Sturm AW, Shah NS. Nosocomial Transmission of Extensively Drug-Resistant Tuberculosis in a Rural Hospital in South Africa. The Journal Of Infectious Diseases 2012, 207: 9-17. PMID: 23166374, PMCID: PMC3523793, DOI: 10.1093/infdis/jis631.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsCluster AnalysisCross InfectionDrug Therapy, CombinationEthambutolExtensively Drug-Resistant TuberculosisFemaleGenotypeHIV InfectionsHospitals, RuralHumansIsoniazidMaleMutationMycobacterium tuberculosisPolymorphism, Restriction Fragment LengthPrevalencePyrazinamideRetrospective StudiesRifampinSequence Analysis, DNASouth AfricaConceptsDrug-resistant tuberculosisHuman immunodeficiency virusNosocomial transmissionEpidemiologic linkExtensively Drug-Resistant TuberculosisPoor infection controlSmear-positive tuberculosisMultidrug-resistant tuberculosisHigh HIV prevalencePoint-source outbreakGlobal public health threatPublic health threatResistance-determining regionXDR tuberculosisImmunodeficiency virusHIV prevalenceObservational studyInfection controlRural hospitalsPatientsTuberculosisTugela FerryFragment length polymorphism analysisHealth threatRestriction fragment length polymorphism analysisA Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South Africa
Mosam A, Shaik F, Uldrick TS, Esterhuizen T, Friedland GH, Scadden DT, Aboobaker J, Coovadia HM. A Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2012, 60: 150-157. PMID: 22395672, PMCID: PMC3360837, DOI: 10.1097/qai.0b013e318251aedd.Peer-Reviewed Original ResearchConceptsHIV-KSKing Edward VIII HospitalSymptomatic visceral diseaseActive antiretroviral therapyOpen-label trialTreatment-naive patientsTertiary referral centerAdministration of chemotherapyHAART armUrgent chemotherapyAntiretroviral therapyReferral centerVisceral diseaseTreat analysisKaposi's sarcomaHAARTChemotherapySaharan AfricaOptimal approachHIVLamivudinePatientsSarcomaStavudineNevirapineSurvival from XDR-TB Is Associated with Modifiable Clinical Characteristics in Rural South Africa
Shenoi SV, Brooks RP, Barbour R, Altice FL, Zelterman D, Moll AP, Master I, van der Merwe TL, Friedland GH. Survival from XDR-TB Is Associated with Modifiable Clinical Characteristics in Rural South Africa. PLOS ONE 2012, 7: e31786. PMID: 22412840, PMCID: PMC3295798, DOI: 10.1371/journal.pone.0031786.Peer-Reviewed Original ResearchConceptsXDR-TB patientsDrug-resistant tuberculosisRetrospective case-control studyXDR-TB casesCommunity-based hospitalCase-control studyGlobal public healthHIV coinfectionMicrobiological correlatesModifiable factorsAvailable interventionsRural South AfricaControl studyPatientsTuberculosisPublic healthSurvivorsSurvivalDaysHospitalMortality
2011
Spread of Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal Province, South Africa
Moodley P, Shah NS, Tayob N, Connolly C, Zetola N, Gandhi N, Friedland G, Sturm AW. Spread of Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal Province, South Africa. PLOS ONE 2011, 6: e17513. PMID: 21655324, PMCID: PMC3104985, DOI: 10.1371/journal.pone.0017513.Peer-Reviewed Original ResearchConceptsMDR-TB casesDrug-resistant tuberculosisXDR-TB casesXDR-TBDrug susceptibility test resultsExtensively Drug-Resistant TuberculosisMDR tuberculosis casesMDR-TB patientsXDR-TB patientsCulture-confirmed casesProvincial referral hospitalCross-sectional studyKwaZulu-Natal ProvinceSource of infectionTB casesNumber of hospitalsReferral hospitalSputum cultureTuberculosis casesScotland hospitalsPatientsHealthcare districtsHospitalClinical diagnosisLaboratory databaseComputer-Based Intervention in HIV Clinical Care Setting Improves Antiretroviral Adherence: The LifeWindows Project
Fisher JD, Amico KR, Fisher WA, Cornman DH, Shuper PA, Trayling C, Redding C, Barta W, Lemieux AF, Altice FL, Dieckhaus K, Friedland G, for the LifeWindows Team. Computer-Based Intervention in HIV Clinical Care Setting Improves Antiretroviral Adherence: The LifeWindows Project. AIDS And Behavior 2011, 15: 1635. PMID: 21452051, DOI: 10.1007/s10461-011-9926-x.Peer-Reviewed Original ResearchConceptsHIV clinical care settingsAdherence support interventionsClinical care sitesClinical care settingsHIV careCare visitsAntiretroviral adherenceControl armCare settingsCare sitesProtocol interventionTreat sampleProtocol sampleSupport interventionsComputer-based interventionsIntervention impactControl participantsInterventionAdherenceHIVPatientsCareHigh levelsClinicARVIncreasing Drug Resistance in Extensively Drug-Resistant Tuberculosis, South Africa - Volume 17, Number 3—March 2011 - Emerging Infectious Diseases journal - CDC
Shah NS, Richardson J, Moodley P, Moodley S, Babaria P, Ramtahal M, Heysell SK, Li X, Moll AP, Friedland G, Sturm AW, Gandhi NR. Increasing Drug Resistance in Extensively Drug-Resistant Tuberculosis, South Africa - Volume 17, Number 3—March 2011 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2011, 17: 510-513. PMID: 21392446, PMCID: PMC3166021, DOI: 10.3201/eid1703.101363.Peer-Reviewed Original ResearchConceptsExtensively Drug-Resistant TuberculosisTuberculosis drug susceptibility testingDrug-resistant Mycobacterium tuberculosisInfectious Diseases journal - CDCDrug-resistant TBDrug-resistant tuberculosisDrug susceptibility testingEffective treatmentAvailable drugsDrug resistanceSusceptibility testingMycobacterium tuberculosisTuberculosisDrugsPatients